Human-derived normal mesenchymal stem/stromal cells in anticancer therapies
Cheng Zhang, Shijie Yang, Qin Wen, Jiang F. Zhong, Xuelian Chen, Andres Stucky, Michael F. Press, Xi Zhang · Journal of Cancer · 2016
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · review · 2016
Abstract
The tumor microenvironment (TME) not only plays a pivotal role during cancer progression and metastasis, but also has profound effects on therapeutic efficacy. Stromal cells of the TME are increasingly becoming a key consideration in the development of active anticancer therapeutics. However, dispute concerning the role of stromal cells to fight cancer continues because the use of mesenchymal stem/stromal cells (MSCs) as an anticancer agent is dependent on the specific MSCs subtype, in vitro or in vivo conditions, factors secreted by MSCs, types of cancer cell lines and interactions between MSCs, cancer cells and host immune cells.
In this review, we mainly focus on the role of human-derived normal MSCs in anticancer therapies. We first discuss the use of different MSCs in the therapies for various cancers. We then focus on their anticancer mechanism and clinical application.
Open the resolved locator · 10.7150/jca.16792
Metadata licence: OpenAlex metadata (CC0)